Fantastic breakthrough in cancer treatment – ivermectin, mebendazole and fenbendazole

The discussion between Joe Rogan and Mel Gibson raises important questions about access to effective treatments and how the pharmaceutical industry and medical institutions handle information about therapeutic alternatives. Although the use of ivermectin, fenbendazole, or methylene blue is not officially recognized as a treatment for cancer, there are increasing reports of individuals claiming that these substances have helped them. It is essential for scientific research to continue in order to truly evaluate the effectiveness of these treatments and ensure that patients receive the best possible options for their health.

Did you know that almost one in two people will be diagnosed with cancer in their lifetime? While these statistics are nothing to cheer about, a recent groundbreaking discovery brings a new ray of hope in cancer treatment. A study published in 2024 in the Journal of Orthomolecular Medicine presents a new protocol that offers a promising option for cancer treatment and could bring a significant change to current treatment methods.

Protocol basics: ivermectin, mebendazole and fenbendazole

This innovative protocol is based on three specific compounds: ivermectin, mebendazole and fenbendazole. The combination of these compounds is directly linked to attacking the interfaces between mitochondria and cancer stem cells, which allows the energy supply to cancer cells to be interrupted. The new approach has the potential to fundamentally change current cancer treatment methods by targeting stem cells directly.

The protocol is not the result of a single researcher: it has been developed by more than 16 universities and research centers in countries such as the United States, Canada, France and Mexico. It is an international collaboration, jointly developed by renowned institutions, which could have a profound impact on the fight against cancer.

The essence of the Warburg effect

Healthy cells rely on oxidative phosphorylation (OXPHOS) in mitochondria for energy production in the presence of oxygen. Unlike glycolysis under anaerobic conditions, which takes place in the absence of oxygen, cancer cells primarily use aerobic glycolysis, even in the presence of oxygen. This means that glucose is converted to lactic acid rather than water and carbon dioxide as in normal oxidative phosphorylation. So, during the Warburg effect, cancer cells use glycolysis for energy production, even though oxygen is available for OXPHOS.

Why is it beneficial for cancer cells?

The Warburg effect – or aerobic glycolysis – provides rapid energy production, which helps cancer cells to grow and multiply rapidly. Although this process is less efficient in terms of ATP production, it is still beneficial for cancer cells because they can quickly obtain energy while also producing by-products (such as nucleotides and lipids) that are needed for cell growth.

The role of the relationship between stem cells and mitochondria in cancer

The mitochondria-stem cell connection (MSCC) theory hypothesizes that the cancer process results from a long-term disruption of energy production in stem cells. Due to insufficient cellular oxidative phosphorylation processes (OxPhos), stem cells enter a state in which they turn into cancer stem cells (CSCs) and function with abnormal energy consumption, leading to the development of malignant tumors.

This theory combines two main approaches: the cancer stem cell theory and the metabolic theory. Based on insights from molecular biology, pharmacology and clinical research, this study proposes a hybrid orthomolecular protocol targeting MSCC. The protocol includes seven therapeutic recommendations, which include orthomolecules, drugs and complementary therapies.

The aim is for these treatments to act together in an additive and synergistic manner to improve OxPhos function, prevent the utilization of primary energy sources (glucose and glutamine) by cancer cells, and target cancer stem cells and metastases. A number of experiments suggest that targeting MSCC may be an effective approach to treat cancer.

Why is this discovery so important?

The number of cancer cases has risen dramatically in recent decades. While the incidence of cancer in the United States was only 20% in the 1950s, it is now approaching 50%. This means that one in two people may be diagnosed with cancer during their lifetime. Against this background, a new treatment protocol using ivermectin and benzimidazole compounds such as mebendazole and fenbendazole could open up new possibilities for treating cancer.

What is ivermectin and why is it important?

First discovered in the 1970s, ivermectin was awarded the Nobel Prize in Medicine in 2015 by Satoshi Omura and William Campbell for the discovery of its antiparasitic properties. Ivermectin has become known as an effective antiparasitic and is widely used to treat various parasitic infections. However, ivermectin is not only effective against parasites, but also against viruses: it has been shown to be effective against influenza, avian influenza, SARS, HIV-1, as well as a number of other RNA viruses such as Zika, malaria, Tanguy, yellow fever, West Nile and Hendra viruses. One of its mechanisms of action is to prevent viruses from replicating. It inhibits virus entry into the nucleus and cytoplasm, thus preventing virus replication. In addition to its remarkable efficacy, ivermectin has been shown to be safe with a low risk of toxicity when used according to medical protocols.

Ivermectin, a deworming drug originally introduced to treat various neglected tropical diseases (NTDs) for human use, has also gained attention in recent research areas such as cancer, malaria, tuberculosis and the biggest pandemic of our time, SARS-CoV-19.

Dosages used in the protocol

The dose of ivermectin in this new protocol will vary depending on the type and severity of the cancer. The recommended dose is between 0.5 mg/kg and 1 mg/kg body weight. In milder cases, 0.5 mg/kg three times a week is recommended, while in more severe cases up to 1 mg/kg daily can be used. The protocol is designed to disrupt the energy supply to cancer cells, in particular by blocking connections between stem cells and mitochondria.

For low-grade cancer:

• Dosage: 0.5 mg/kg body weight, 3 times weekly (Guzzo et al., 2002).

For intermediate-stage cancer:

• Dosage: 1 mg/kg body weight, 3 times weekly (Guzzo et al., 2002).

For advanced stage cancer:

• Dosage: 1 mg/kg bw/day (de Castro et al., 2020) or 2 mg/kg bw/day (Guzzo et al., 2002).

Safety: these doses are tolerated by humans (Guzzo et al., 2002).

In addition, the protocol also uses benzimidazole compounds such as mebendazole and fenbendazole. For mebendazole, the recommended dose ranges from 200 mg to 1500 mg, depending on the stage of the cancer. For fenbendazole, the recommended dose is 1000 mg three times a week. Mebendazole, known as Vermox, is a broad-spectrum antiparasitic agent. It is often used for de-worming children and adults, especially in places where parasite infestations are common. The use of mebendazole or fenbendazole in the protocol is particularly important because these compounds can be particularly effective against glutamine-dependent cancer cells, which often use glutamine as an energy source. For these tumor types, a combination of diazooxonorleucine (DON) and benzimidazole compounds is recommended.

Benzimidazoles and DON
For low-grade cancer:

• Mebendazole dose: 200 mg/day (Dobrosotskaya et al., 2011).

For intermediate-stage cancer:

• Mebendazole dose: 400 mg/day (Chai et al., 2021).

For high-grade cancer:

• Mebendazole dose: 1 500 mg/day (Son et al., 2020) or fenbendazole 1 000 mg, 3 times weekly (Chiang et al., 2021).

Safety: these doses are tolerated by humans (Chai et al, 2021; Chiang et al, 2021; Son et al, 2020).

Ivermectin Experimental Cancer Protocols (Dr. William Makis, oncologist)

Warning:
This is not a recommendation for use by patients, but only information and research material for clinicians.

DON (Diazooxonorleucine):

• Intramuscular or intravenous administration: 0.2-0.6 mg/kg bw/day
• Oral administration: 0.2-1.1 mg/kg bw/day (Lemberg et al., 2018; Rais et al., 2022).

Important note: Benzimidazoles are more readily available, but for metastatic tumors that are highly glutamine-dependent, a combination of DON and benzimidazoles is recommended (Mukherjee et al., 2023).

How does ivermectin work against parasites?

The unique feature of ivermectin is that it does not kill parasites through toxicity but rather by using a complex mechanism that blocks the parasites’ chloride channels, causing paralysis, which ultimately leads to their death. Ivermectin also interferes with the parasites’ neurotransmitters, particularly acetylcholine, further weakening them. Additionally, ivermectin does not harm beneficial gut bacteria, ensuring that the body’s natural balance remains unaffected.

The Antiviral Effect of Ivermectin

Ivermectin works by blocking viruses from entering the cell nucleus, thereby preventing their replication within the host cell. This mechanism makes ivermectin effective against a wide range of viral infections, strengthening its position among antiviral agents. Moreover, the use of ivermectin has shown remarkable results in the treatment of COVID-19, despite ongoing controversies and intense debates surrounding it.

Why Is This Discovery Significant?

The significance of this new protocol lies in its unique approach to treating cancer cells by directly disrupting their cellular energy supply, targeting the connections between cancer stem cells and mitochondria. The protocol utilizes compounds that have received little attention in cancer treatment but have now been proven to play a key role in fighting cancer cells. Researchers and doctors worldwide recognize the importance of this protocol and hope that the combination of ivermectin, mebendazole, and fenbendazole will offer new hope to patients for whom conventional treatments have not provided sufficient relief. As the protocol is backed by international collaboration and thorough research, it is likely to become widely adopted in the coming years and provide an effective alternative in cancer treatment.

What Additional Treatments Can Be Used in the Protocol?

In addition to ivermectin and benzimidazole compounds, the protocol includes several complementary treatments aimed at overcoming cancer cell resistance and strengthening the immune system. Let’s take a look at the most important ones:

1. The Role of Vitamin D in Cancer Treatment

Vitamin D is a crucial element in this modern cancer treatment protocol. The author recommends taking 10,000 international units (IU) of vitamin D3 (equivalent to 250 micrograms) per day, administered sublingually so that it passes through the mucosa directly into the bloodstream, increasing absorption efficiency. This dosage is significantly higher than the generally recommended 1,000 or 2,000 IU.

However, the protocol goes even further: it suggests a daily intake of 50,000 IU of vitamin D3—five times the amount the author himself uses. A case study conducted by a researcher from Boston also demonstrates that taking high doses (50,000 IU) of vitamin D3 over a long period did not cause any side effects and even led to significant benefits.

For All Stages of Cancer:

Dosage:

• 50,000 IU/day if blood level ≤ 30 ng/mL
• 25,000 IU/day if blood level is between 30-60 ng/mL
• 5,000 IU/day if blood level is between 60-80 ng/mL

Target Blood Level: The blood level of vitamin D (25-hydroxyvitamin D) should reach 80 ng/mL (Kennel et al., 2010; Mohr et al., 2014; Mohr et al., 2015). This level is not toxic (Holick et al.).

• Maintenance Dose: Once the desired level is reached, a maintenance dose of 2,000 IU/day is recommended (Ekwaru et al., 2014).
• Monitoring: Vitamin D levels should be measured every two weeks for high doses and monthly for lower doses.

2. Vitamin C, an Immune System Booster

Another important component of the protocol is vitamin C, which is administered intravenously to cancer patients at a dose of 1.5 grams per kilogram of body weight per day. This is a significantly higher amount than typically recommended.

Intravenous Vitamin C
For moderate to high-grade cancer:

• Dosage: 1.5 g/kg body weight per day, 2-3 times per week (Fan et al., 2023).
• Safety: Non-toxic dose for cancer patients (Wang, F., et al., 2019).

For those who do not have access to intravenous vitamin C, I recommend liposomal vitamin C. This type of vitamin C has the unique feature of being surrounded by a liposomal layer, allowing it to penetrate cells more easily and remain active for a longer period than other forms of vitamin C.

3. Zinc and the Fight Against Cancer Cells

The protocol also recommends 1 mg/kg of zinc per day for patients. For example, a person weighing 80 kg would need 80 mg of zinc daily. Reaching adequate zinc levels (80-120 micrograms per deciliter) is essential for boosting the immune response against cancer cells. Zinc supports the immune system and plays a vital role in strengthening the body’s natural defenses.

For all stages of cancer:

• Dosage: 1 mg/kg body weight per day, which is a non-toxic dose for cancer patients (Hoppe et al., 2021; Lin et al., 2006).
• Reference Blood Level Range: Serum zinc levels should be between 80-120 μg/dL (Mashhadi et al., 2016; Yokokawa et al., 2020).
  • Maintenance Dose: Once the desired level is reached, 5 mg/day is recommended for maintenance (Li et al., 2022).

Monitoring: It is recommended to check your blood zinc levels monthly.

4. Hyperbaric Oxygen Therapy: Using Oxygen to Fight Tumors

Hyperbaric oxygen therapy is based on inhaling 100% oxygen in a specialized chamber at a pressure higher than normal atmospheric pressure, supplying the body with oxygen. Since tumors often grow in an oxygen-deficient environment (hypoxia), high concentrations of oxygen inhibit tumor cell growth and support the immune system in fighting cancer. According to numerous studies, hyperbaric oxygen therapy inhibits cancer cell proliferation and also helps target metastases.

5. Energy Restriction of Tumors: The Role of Diet and Amino Acids

One of the most important energy sources for cancer cells is sugar, or more specifically, glucose from the bloodstream. For this reason, a low-carbohydrate or ketogenic diet is often recommended in the fight against cancer, as it significantly reduces glucose levels in the body, leading to an energy deficit for cancer cells. If there is not enough glucose in the blood, cancer cells literally “starve to death”, which inhibits their growth and reproduction.

The ketogenic diet is one of the most important lifestyle modifications recommended by the protocol. The main principle of the ketogenic diet is to minimize carbohydrate intake, so the body gets its energy from fats instead. This approach can be highly effective against cancer, as glucose is the primary energy source for cancer cells. By depriving cancer cells of this source, the ketogenic diet reduces cancer cell growth and promotes apoptosis (cell death). Additionally, the ketogenic diet helps reduce inflammation and improve cellular respiration.

However, in addition to glucose, other components can also provide energy for cancer cells – such as certain amino acids, including glutamine and branched-chain amino acids (BCAAs) like leucine, isoleucine, and valine.

• Glutamine is a particularly important amino acid for cancer cells because many types of cancer can use it for energy. In the body, glutamine originates not only from muscles but also from intestinal cells, as these cells utilize and store a significant portion of the consumed glutamine. This means that the primary source of circulating glutamine does not come from food but rather from muscle tissue breakdown. If the body is not accustomed to fasting or ketosis, even a few hours of fasting can trigger muscle breakdown, increasing blood glutamine levels.

• BCAAs (Leucine, Isoleucine, Valine) also play a key role in cancer growth, as they have an anabolic effect on tumor cells, promoting their development. Reducing the intake of these amino acids in the diet may have a positive effect in fighting tumors.

High-protein diets, especially those rich in animal proteins such as meat, contain high levels of BCAAs and glutamine, which can be harmful to cancer patients. Collagen-based proteins, on the other hand, contain lower amounts of BCAAs and glutamine, making them a better choice for those looking to limit amino acid levels in the bloodstream.

In addition to reducing total protein intake, it is also essential to ensure that the majority of protein intake comes from collagen-based sources.

6. Regular Exercise to Support Mitochondria

Intense, non-cardio exercise plays an important role in the protocol, as it increases the number of mitochondria and supports their efficient function. Mitochondria are the energy centers of cells, and their healthy operation is essential in the fight against cancer cells. The protocol recommends 45-75 minutes of exercise, three times per week, which raises heart rate and improves cellular respiration.

The Role of Exercise in Reducing Blood Amino Acids: Research shows that muscle-building workouts, such as weight training or short sprints, can significantly lower blood amino acid levels, particularly glutamine and BCAAs. This occurs because, during muscle growth, the body takes in more amino acids for muscle building than it releases, causing amino acids to flow from the bloodstream into the muscles. In this way, muscles act as a “sponge” that absorbs excess amino acids, making them less available to tumor cells.

The Potential Role of SARMs: Selective Androgen Receptor Modulators (SARMs) are experimental compounds that help preserve muscle mass even with a low-calorie intake. These agents work by specifically increasing androgen receptor activity in muscles, exerting an anabolic effect without stimulating tumor cell growth. As a result, muscles can absorb more amino acids while reducing blood amino acid levels, creating an unfavorable environment for tumors.

Alternative for Severe Cancer Patients: For patients with advanced cancer who cannot engage in intense exercise, the protocol recommends 45-60 minutes of oxygen therapy in a hyperbaric chamber 2-3 times per week as an alternative approach.

7. Fasting as a Natural Cellular Regenerator

Fasting, especially longer fasting periods, is also a key element of the protocol. Fasting helps activate the body’s stem cells while simultaneously depriving cancer cells of glucose, which is essential for their survival. This method not only helps destroy cancer cells but also enhances treatment effectiveness by promoting healing processes and supporting natural cell death (apoptosis).

The Role of Caloric Restriction and Ketosis: Low-calorie intake, intermittent fasting, and the ketogenic diet are all methods that reduce blood amino acid levels and promote ketosis, leading to: increased growth hormone levels and decreased insulin-like growth factor 1 (IGF-1). This is significant because high IGF-1 levels in the liver can stimulate tumor growth, whereas IGF-1 derived from muscles has a positive effect on muscle growth but does not stimulate tumor cell proliferation.

Disclaimer

This discovery not only brings new hope in the fight against cancer but also paves the way for holistic medical approaches based on orthomolecular principles, which could lead to significant changes in medical practice in the future. We hope this breakthrough will truly come to fruition, but let’s not get our hopes too high – Big Pharma is doing everything in its power to suppress and silence such efforts. Their primary interest is in selling as many expensive drugs as possible, rather than providing patients with affordable and truly effective treatments—after all, a cured patient is no longer a source of profit…

• Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol

Many of the researchers are well-known experts in cancer metabolomics, integrative oncology, and functional medicine.

• Ilyes Baghli – An expert in integrative medicine.
• William Makis – Specializes in nuclear medicine and cancer diagnostics.
• Paul E. Marik – A renowned expert in critical care and sepsis research.
• Michael J. Gonzalez – Researcher in orthomolecular and nutritional oncology.
• William B. Grant – Expert in vitamin D and cancer prevention.
• Ron Hunninghake & Thomas E. Levy – Active in integrative oncology, particularly vitamin C therapy.
• Homer Lim – Specializes in functional and integrative cancer therapies.
• Richard Z. Cheng – Head of research in cancer metabolism and nutrition.
• Igor Bondarenko – Expert in oncology and immunotherapy.
• Paul Bousquet – Specialist in inflammation research.
• Roberto Ortiz – Focuses on nutritional therapies.
• Mignonne Mary – Expert in functional medicine and immunomodulation.
• Dominic P. D’Agostino – Researcher in metabolic therapy and the ketogenic diet.
• Pierrick Martinez – Investigates the link between inflammation and immunity in cancer.

All of them are working on the development of metabolic cancer therapies, combining orthomolecular, nutritional, and pharmaceutical approaches.